Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
The Primary Objective is to evaluate the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.

The Secondary Objective is to evaluate the pharmacokinetics of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.
Chronic Lymphocytic Leukemia|B-cell Lymphomas
DRUG: DTRMWXHS-12
Number of participants with adverse events, Confirm the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule, Starting from date of first dose up to 30 days after last dose
Plasma concentrations of DTRMWXHS-12, DTRMWXHS-12 Pharmacokinetics, Days 1-28 (first treatment cycle)
The Primary Objective is to evaluate the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.

The Secondary Objective is to evaluate the pharmacokinetics of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.